AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: ENHERTU (Daiichi Sankyo, Inc.) (enhertu.com)
This is a benchmark for low-BS communication in the pharmaceutical space. It replaces marketing hyperbole with regulatory precision, providing dense technical evidence and clear safety boundaries for every claim made.
To reach a near-zero score, replace the emotional H1 ‘Sure, HER2-positive metastatic breast cancer will try to take it all’ with a direct clinical outcome statement. Move the clinical trial comparison footnote (comparing against taxane-based chemotherapy) directly into the body text to reduce reliance on small-print verification. Ensure all clinical trial claims link directly to ClinicalTrials.gov registry numbers for maximum transparency. Finally, remove the marketing term ‘breakthrough’ in favor of specific statistical significance data in the hero section.
The Information Density is exceptionally high, with body text dominated by technical clinical specifications such as IHC 3+ status, fam-trastuzumab deruxtecan-nxki active ingredients, and specific dosing forms. Fluff is limited to the emotional H1 marketing campaign ‘Not Today’ and the phrase ‘biggest breakthrough… in over a decade,’ but even these are anchored by specific trial comparison footnotes. The ratio of clinical nouns to marketing adjectives is roughly 8:1.
Most sites "have schema," but AI still cannot understand what their pages represent. Run a Structured Data AI Audit to see what entity types your pages actually resolve into.
There is zero semantic drift observed between the homepage and sub-pages. The homepage H1 establishes the drug as an ‘FDA-approved treatment for several types of cancer,’ and the sub-pages for breast and lung cancer provide granular, consistent details about those exact indications. The transition from general availability on the homepage to specific eligibility criteria on the sub-pages is logically sound and medically precise.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
Trust theatre is non-existent as the site avoids the typical ‘customer testimonial’ trap found in high-BS sites. Instead of review_count, it relies on clinical trial results and provides direct proof_links to ‘Prescribing Information’ and ‘Medication Guides.’ The only reason for a 1-point score is the use of the marketing superlative ‘breakthrough’ without an immediate peer-reviewed citation in the hero section, though it is footnoted later.
Proof density is at the maximum possible level for a commercial medical site. Every major efficacy claim is linked to clinical studies that measured response duration and patient counts. The site provides specific technical specifications (100 mg lyophilized powder) and administration routes (IV infusion), leaving no room for vague assertions typical of low-substance websites.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
While the site uses standard pharmaceutical template fingerprints like ‘Patient Resources’ and ‘For Healthcare Professionals,’ the content is highly unique to the ENHERTU brand. It avoids generic value props by defining its specific ‘mechanism of action’ as an antibody-drug conjugate (ADC). The branding is differentiated by the ‘Not Today’ campaign, which is specific to this product’s patient-facing identity.
There are no authority gaps; the site provides comprehensive schema_json identifying Daiichi Sankyo as the creator and linking to high-authority nodes like Wikipedia for the drug and manufacturer. The inclusion of ‘Boxed WARNINGS’ and detailed pregnancy/breastfeeding warnings demonstrates a high level of regulatory authority and transparency. The technical implementation is professional with no broken hierarchies or missing structured data.
The performance claims are remarkably grounded, with the site explicitly stating that ENHERTU is ‘still being studied to confirm these results’ for certain indications. Marketing tone is present in the ‘Hopeful woman at beach’ imagery, but it is immediately balanced by the legal disclaimer ‘Not actual patients.’ There are no bold claims of ‘curing’ cancer, only clinical response measurements.
Medical Devices, Pharma & Biotech BS: ENHERTU (Daiichi Sankyo, Inc.) (enhertu.com)
The site perfectly matches the Pharma & Biotech category, focusing on a specific prescription medicine with detailed clinical indications. The content is heavily structured around regulatory requirements, including FDA approval statuses and pharmacovigilance safety information.
AI cannot build a coherent graph if the same page resolves into multiple identities. Explore the URL & Canonical Hygiene Technical Framework to understand how identity stability prevents duplicate embeddings and semantic drift.
“The score of 10 was primarily driven by Information Density and Commodity Fingerprint, reflecting the presence of standard marketing slogans ('Not Today') and pharma-industry clichés ('breakthrough'). All other pillars scored near zero due to the site's intense focus on clinical evidence, regulatory compliance, and robust structured data.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 20, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at ENHERTU (Daiichi Sankyo, Inc.) to view the most current version of their content and see directly what the company offers.